Schlenk, R. F., Montesinos, P., Romero-Aguilar, A., Vrhovac, R., Patkowska, E., Kim, H.-J., … Erba, H. P. (2022). Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial. In Blood (Vol. 140, pp. 2130–2132). American Society of Hematology. https://doi.org/10.1182/blood-2022-169011

Schlenk, Richard F., Pau Montesinos, Antonio Romero-Aguilar, Radovan Vrhovac, Elżbieta Patkowska, Hee-Je Kim, Pavel Zak, et al. “Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial.” In Blood, 140:2130–32. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-169011.

Schlenk RF, Montesinos P, Romero-Aguilar A, Vrhovac R, Patkowska E, Kim H-J, et al. Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial. In: Blood. American Society of Hematology; 2022. p. 2130–2.

Schlenk, Richard F., et al. “Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial.” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 2130–32. Crossref, doi:10.1182/blood-2022-169011.

Schlenk RF, Montesinos P, Romero-Aguilar A, Vrhovac R, Patkowska E, Kim H-J, Zak P, Wang P-N, Hanyok J, Liu L, Kamel YM, Benzohra A, Lesegretain A, Cortes JE, Sekeres MA, Dombret H, Amadori S, Wang J, Perl AE, Levis MJ, Erba HP. Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial. Blood. American Society of Hematology; 2022. p. 2130–2132.